Dynavax stock

Dynavax stock DEFAULT

Dynavax

$18.23

$0.00(0.00%)As of 8:36 PM UTC after-hours

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Dynavax and other ETFs, options, and stocks.

Sign up

About DVAX

Dynavax Technologies Corp. operates as a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older.

Headquarters

Emeryville, California

MarketWatchOct 18

Dynavax Shares Rise 11% Premarket on Results for Covid-19 Vaccine Candidate

By Chris Wack Dynavax Technologies Corp. shares rose 11% to $18.80 in premarket trading after the company said Valneva SE reported positive topline results fro

DVAX Earnings

Q1 FY20

Q2 FY20

Q3 FY20

Q4 FY20

Q1 FY21

Q2 FY21

Q3 FY21

Actual

Expected Nov 4, After Hours

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure

Sours: https://robinhood.com/stocks/DVAX

Dynavax Technologies Corp (NASDAQ:DVAX)

Most stock quote data provided by BATS. Market indices are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET. Disclaimer. Morningstar: © 2019 Morningstar, Inc. All Rights Reserved. Factset: FactSet Research Systems Inc.2019. All rights reserved. Chicago Mercantile Association: Certain market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved. Dow Jones: The Dow Jones branded indices are proprietary to and are calculated, distributed and marketed by DJI Opco, a subsidiary of S&P Dow Jones Indices LLC and have been licensed for use to S&P Opco, LLC and CNN. Standard & Poor's and S&P are registered trademarks of Standard & Poor's Financial Services LLC and Dow Jones is a registered trademark of Dow Jones Trademark Holdings LLC. All content of the Dow Jones branded indices © S&P Dow Jones Indices LLC 2019 and/or its affiliates.

© 2021 Cable News Network. A Warner Media Company. All Rights Reserved.
CNN Sans™ & © 2016 Cable News Network.

Sours: https://money.cnn.com/quote/forecast/forecast.html?symb=DVAX
  1. Sims 4 backstory generator
  2. Hofstra sports division
  3. Sewing scrap caddy
  4. Cartoon ocean underwater
  5. Zandalar tribe rep guide

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock quotes are delayed as per exchange requirements. Fundamental company data and analyst estimates provided by FactSet. Copyright 2019© FactSet Research Systems Inc. All rights reserved. Source: FactSet

Indexes: Index quotes may be real-time or delayed as per exchange requirements; refer to time stamps for information on any delays. Source: FactSet

Markets Diary: Data on U.S. Overview page represent trading in all U.S. markets and updates until 8 p.m. See Closing Diaries table for 4 p.m. closing data. Sources: FactSet, Dow Jones

Stock Movers: Gainers, decliners and most actives market activity tables are a combination of NYSE, Nasdaq, NYSE American and NYSE Arca listings. Sources: FactSet, Dow Jones

ETF Movers: Includes ETFs & ETNs with volume of at least 50,000. Sources: FactSet, Dow Jones

Bonds: Bond quotes are updated in real-time. Sources: FactSet, Tullett Prebon

Currencies: Currency quotes are updated in real-time. Sources: FactSet, Tullett Prebon

Commodities & Futures: Futures prices are delayed at least 10 minutes as per exchange requirements. Change value during the period between open outcry settle and the commencement of the next day's trading is calculated as the difference between the last trade and the prior day's settle. Change value during other periods is calculated as the difference between the last trade and the most recent settle. Source: FactSet

Data are provided 'as is' for informational purposes only and are not intended for trading purposes. FactSet (a) does not make any express or implied warranties of any kind regarding the data, including, without limitation, any warranty of merchantability or fitness for a particular purpose or use; and (b) shall not be liable for any errors, incompleteness, interruption or delay, action taken in reliance on any data, or for any damages resulting therefrom. Data may be intentionally delayed pursuant to supplier requirements.

Mutual Funds & ETFs: All of the mutual fund and ETF information contained in this display, with the exception of the current price and price history, was supplied by Lipper, A Refinitiv Company, subject to the following: Copyright 2019© Refinitiv. All rights reserved. Any copying, republication or redistribution of Lipper content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Lipper. Lipper shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Cryptocurrencies: Cryptocurrency quotes are updated in real-time. Sources: CoinDesk (Bitcoin), Kraken (all other cryptocurrencies)

Calendars and Economy: 'Actual' numbers are added to the table after economic reports are released. Source: Kantar Media

Sours: https://www.wsj.com/market-data/quotes/DVAX
DVAX Stock Could Soar Even Higher!! Dynavax Technologies Corporation (NASDAQ:DVAX)

Dynavax TechnologiesNasdaqCM:DVAX Stock Report

Dynavax Technologies Competitors

Price History & Performance

Historical stock prices
Current Share PriceUS$17.55
52 Week HighUS$3.58
52 Week LowUS$20.96
Beta1.32
1 Month Change17.86%
3 Month Change81.12%
1 Year Change323.91%
3 Year Change32.15%
5 Year Change72.91%
Change since IPO-81.33%

Recent News & Updates

Oct 16

Dynavax And TLR Biology: Long-Delayed But Outstanding Success

Dynavax developed CpG 1018 many years ago. The coronavirus pandemic gave CpG 1018 a vast market to tap. The future looks good for DVAX.

Oct 02
These 4 Measures Indicate That Dynavax Technologies (NASDAQ:DVAX) Is Using Debt Reasonably Well

These 4 Measures Indicate That Dynavax Technologies (NASDAQ:DVAX) Is Using Debt Reasonably Well

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

Shareholder Returns

DVAXUS BiotechsUS Market
7D-2.8%1.7%4.0%
1Y323.9%15.6%30.5%

Return vs Industry: DVAX exceeded the US Biotechs industry which returned 13.6% over the past year.

Return vs Market: DVAX exceeded the US Market which returned 30% over the past year.

Price Volatility

DVAX volatility
DVAX Beta1.32
Industry Beta0.98
Market Beta1

Stable Share Price: DVAX is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.

Volatility Over Time: DVAX's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B.

Dynavax Technologies Fundamentals Summary

DVAX fundamental statistics
Market CapUS$2.01b
Earnings (TTM)-US$5.70m
Revenue (TTM)US$169.07m

Earnings & Revenue

DVAX income statement (TTM)
RevenueUS$169.07m
Cost of RevenueUS$80.55m
Gross ProfitUS$88.51m
ExpensesUS$94.21m
Earnings-US$5.70m

Last Reported Earnings

Jun 30, 2021

Earnings per share (EPS)-0.05
Gross Margin52.35%
Net Profit Margin-3.37%
Debt/Equity Ratio263.8%

How did DVAX perform over the long term?

See historical performance and comparison

Valuation

Is Dynavax Technologies undervalued compared to its fair value and its price relative to the market?

24.16x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: DVAX ($17.55) is trading above our estimate of fair value ($12.9)

Significantly Below Fair Value: DVAX is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: DVAX is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: DVAX is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate DVAX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: DVAX is overvalued based on its PB Ratio (24.2x) compared to the US Biotechs industry average (2.9x).


Future Growth

How is Dynavax Technologies forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

-14.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: DVAX's earnings are forecast to decline over the next 3 years (-14.2% per year).

Earnings vs Market: DVAX is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: DVAX's is expected to become profitable in the next 3 years.

Revenue vs Market: DVAX's revenue is expected to decline over the next 3 years (-2.7% per year).

High Growth Revenue: DVAX's revenue is forecast to decline over the next 3 years (-2.7% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if DVAX's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Dynavax Technologies performed over the past 5 years?

4.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: DVAX is currently unprofitable.

Growing Profit Margin: DVAX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: DVAX is unprofitable, but has reduced losses over the past 5 years at a rate of 4.9% per year.

Accelerating Growth: Unable to compare DVAX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: DVAX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4.9%).


Return on Equity

High ROE: DVAX has a negative Return on Equity (-6.84%), as it is currently unprofitable.


Financial Health

How is Dynavax Technologies's financial position?


Financial Position Analysis

Short Term Liabilities: DVAX's short term assets ($583.9M) exceed its short term liabilities ($204.6M).

Long Term Liabilities: DVAX's short term assets ($583.9M) exceed its long term liabilities ($359.9M).


Debt to Equity History and Analysis

Debt Level: DVAX's debt to equity ratio (263.8%) is considered high.

Reducing Debt: Insufficient data to determine if DVAX's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Whilst unprofitable DVAX has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.

Forecast Cash Runway: DVAX is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 4.2% per year.


Dividend

What is Dynavax Technologies's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate DVAX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate DVAX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if DVAX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if DVAX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of DVAX's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.1yrs

Average management tenure


CEO

Mr. Ryan Spencer serves as the Chief Executive Officer and Director of Dynavax Technologies Corp. since December 16, 2019. He had been Co-President and Co-Principal Executive Officer of Dynavax Technologie...


CEO Compensation Analysis

Compensation vs Market: Ryan's total compensation ($USD1.52M) is below average for companies of similar size in the US market ($USD3.53M).

Compensation vs Earnings: Ryan's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: DVAX's management team is not considered experienced ( 1.1 years average tenure), which suggests a new team.


Board Members

Experienced Board: DVAX's board of directors are considered experienced (3.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4.8%.


Top Shareholders

Company Information

Dynavax Technologies Corporation's employee growth, exchange listings and data sources


Key Information

  • Name: Dynavax Technologies Corporation
  • Ticker: DVAX
  • Exchange: NasdaqCM
  • Founded: 1996
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$2.014b
  • Shares outstanding: 114.76m
  • Website: https://www.dynavax.com

Number of Employees


Location

  • Dynavax Technologies Corporation
  • 2100 Powell Street
  • Suite 900
  • EmeryVille
  • California
  • 94608
  • United States

Listings


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2021/10/19 23:39
End of Day Share Price2021/10/19 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Sours: https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-dvax/dynavax-technologies

Stock dynavax

Why Shares of Dynavax Technologies, Ocugen, and Valneva Are on the Move Today

What happened

Shares of the COVID-19 vaccine developers Dynavax Technologies(NASDAQ:DVAX), Ocugen(NASDAQ:OCGN), and Valneva(NASDAQ:VALN) are all making moves today. As of 1:32 p.m. EDT,  Dynavax's stock was up 2%, Ocugen's stock was down 3.2%, and Valneva's shares soared 32% higher.

What's driving these moves? The French biopharma Valneva announced this morning that late-stage trial results for its COVID-19 vaccine, VLA2001, produced a stronger overall immune response, with fewer side effects, when compared to AstraZeneca's shot. These results, in turn, are expected to form the basis for regulatory filings for Valneva's vaccine candidate in both the United Kingdom and the European Union. 

Healthcare professional administering a vaccine to a patient.

Image source: Getty Images.

So what

Dynavax's shares are moving higher on this news because Valneva's vaccine uses the biotech's adjuvant known as CpG 1018. An adjuvant is a compound used to boost a vaccine's efficacy. Dynavax thus stands to benefit financially from the vaccine's potential approvals overseas. 

Why is Ocugen's stock slumping on this news? Ocugen has a co-commercialization agreement in place with India's Bharat Biotech for a COVID-19 vaccine called Covaxin. Despite some recent successes on the regulatory front in India, the duo hasn't gotten key regulatory nods from either the U.S. Food and Drug Administration or the World Health Organization yet.

While the news of Valneva and Dynavax's vaccine producing stellar late-stage trial results may not directly impact Ocugen at the end of the day, investors are apparently growing restless about Covaxin's regulatory fate in key developed and emerging markets.

Now what

Should investors buy shares of Dynavax, Ocugen, or Valneva on this news? Dynavax stands to take in over $200 million from its various licensing deals for CpG 1018, and today's news should shore up that revenue estimate. So, yes, Dynavax's stock might be worth picking up. Valneva's stock also comes across as a strong buy. The biopharma's market cap remains under $2 billion, and this vaccine could post sales in the hundreds of millions next year (assuming approval). 

Ocugen's stock, for its part, might also be a worthwhile buy on this pullback. The company has been stuck in neutral because of the slow progress with Covaxin's regulatory process. But this vaccine could play a key role in the fight against the pandemic. As a result, this small-cap biotech may be worth adding to your portfolio today.

Sours: https://www.fool.com/investing/2021/10/18/why-shares-of-dynavax-technologies-ocugen-and-valn/
Billionaire Ray Dalio Bets on These 2 ‘Strong Buy’ Stocks!!

.

Similar news:

.



235 236 237 238 239